compound 13a [PMID: 23639540]   Click here for help

GtoPdb Ligand ID: 8155

Compound class: Synthetic organic
Comment: The discovery of compound 13a is reported in [1], a medicinal chemistry study to identify selective bone morphogenetic protein receptor (BMP) inhibitors. Compound 13a inhibits the majority of Type I receptor serine/threonine kinases to a greater or lesser extent, but is most potent at ALK1 (ACVRL1) and ALK2 (ACVR1) which are activin receptor components, and ALK3 (BMPR1A) and ALK6 (BMPR1B) which are bone morphogenetic protein receptors. Compound 13a has its most potent inhibitory effect on TGFBR2 and VEGFR2, with approximately 25 times lower potency against BMPR2 and AMPK, where reported IC50s are more akin to those at the Type I receptor serine/threonine kinases [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 71.34
Molecular weight 346.15
XLogP 2.95
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O1CCN(CC1)c1ccc(cc1)c1cnc2n(c1)ncc2c1cn[nH]c1
Isomeric SMILES O1CCN(CC1)c1ccc(cc1)c1cnc2n(c1)ncc2c1cn[nH]c1
InChI InChI=1S/C19H18N6O/c1-3-17(24-5-7-26-8-6-24)4-2-14(1)16-9-20-19-18(12-23-25(19)13-16)15-10-21-22-11-15/h1-4,9-13H,5-8H2,(H,21,22)
InChI Key WCDLCPLAAKUJNY-UHFFFAOYSA-N
References
1. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR. (2013)
Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
Bioorg Med Chem Lett, 23 (11): 3248-52. [PMID:23639540]